window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date());gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 15, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

biologics manufacturing

  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    Piramal Pharma takes controlling stake in Yapan Bio

    Piramal Pharma has completed the acquisition of an additional 40.67% [...]

    August 19, 2026
  • Manufacturing & Supply Chain

    University Hospital Cologne selects Celonic for anti-Pseudomonas antibody manufacturing

    University Hospital Cologne has selected Celonic as its CDMO partner [...]

    August 13, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Enzene launches local biomanufacturing model to cut biologics manufacturing costs

    Enzene has launched a biomanufacturing model designed to help governments [...]

    August 3, 2026
  • Drug Delivery & Formulation,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development

    ProBioGen and VarmX partner on second Factor X candidate

    ProBioGen and VarmX have entered a collaboration to develop a [...]

    July 29, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain,Research & Development

    Icosagen completes €45M biologics manufacturing expansion

    Estonian biotechnology company Icosagen has completed a €45 million expansion [...]

    July 2, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    Microbial manufacturing enters a new era of scale and complexity

    As demand grows for increasingly complex biologics, microbial manufacturing is [...]

    June 18, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    Lonza expands DNA-to-IND offering to accelerate biologics development timelines

    Lonza has expanded its integrated DNA-to-IND biologics development offering, introducing [...]

    June 8, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Anixa Biosciences advances breast cancer vaccine toward Phase 2 with Cytovance manufacturing deal

    Anixa Biosciences is advancing its breast cancer vaccine programme towards [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Therapeutic Areas

    ImmuneOncia Therapeutics and Lonza agree manufacturing partnership for PD-L1 antibody Danburstotug

    ImmuneOncia Therapeutics and Lonza have entered into a manufacturing collaboration [...]

    May 5, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Vetter recognised as 2026 CDMO Leadership Awards winner in finished dose category

    Vetter has been named winner in the Finished Dose category [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • $3M funding targets tau-driven neurodegenerative diseases
    Categories: Central Nervous System, Drug Discovery & Development, Research & Development, Therapeutic Areas
  • Cancer vaccine research secures $2.5M NIH award for nanoparticle treatment
    Categories: Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • FDA approves Protagonist’s Mimrylo for polycythemia vera, triggering $275M in payments
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top